BEAM News and Press, Beam Therapeutics Inc. From 10/03/23

2023-10-03 06:27:00 ET This September, Cathie Wood bought shares of Beam Therapeutics (NASDAQ: BEAM) more than a dozen times for two of Ark Invest's exchange-traded funds ( ETF s). At the beginning of October, the biotech stock was the 13th-largest holding in the Ark Geno...

2023-09-29 10:30:00 ET Cathie Wood is trying to get her groove back. The founder, CEO, and primary stock picker for Ark Invest has been in a funk lately. Her largest fund has fallen 10% this month heading into the final trading day of September. This follows a 13% slide in August. She's...

2023-09-27 08:30:00 ET Despite a sizzling start to the year, growth stocks have suddenly found themselves on the outs with investors. Concerns about the global economy, persistently high interest rates, and stubborn levels of inflation have weighed heavily on pure-play growth stocks in the ...

2023-09-22 05:50:00 ET Warren Buffett has been a net seller of stocks in recent months, but it's a different story for Cathie Wood. She's been busy scooping up shares of innovative companies for several of her Ark Invest exchange-traded funds (ETFs). If you're an aggressive investor, here a...

2023-09-08 08:20:00 ET Beam Therapeutics ' (NASDAQ: BEAM) stock has fallen by 40% this year so far, but that hasn't stopped portfolio manager Cathie Wood's ARK Genomic Revolution ETF from loading up on its shares. Most recently, on Aug. 15, she bought more than 20,000 shares, ca...

2023-09-08 07:23:00 ET Would you like to improve your stock-picking chops by learning from the pros? You could wait for the next round of disclosures that institutional investors are required to make four times per year, or you could look at what Cathie Wood and the family of exchange-trade...

CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported new preclinical data demonstrating the ability of its in vivo drug candidate, BEAM-302, to direct...

CAMBRIDGE, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that in August, the first patient was treated with BEAM-201, a quadruplex-edited allogeneic CAR-T ce...

CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management plans to participate in fireside chats during the following September investor confer...

2023-08-29 08:06:00 ET More on Apellis Sticking With Apellis: Navigating Syfovre's Safety Measures In A Volatile Market Apellis Pharmaceuticals, Inc. ( APLS ) Q2 2023 Earnings Call Transcript Apellis Pharmaceuticals, Inc. 2023 Q2 - Results - Earnings Call Present...